432 related articles for article (PubMed ID: 30721443)
1. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
Hussain Y; Drill E; Dang CT; Liu JE; Steingart RM; Yu AF
Breast Cancer Res Treat; 2019 May; 175(1):239-246. PubMed ID: 30721443
[TBL] [Abstract][Full Text] [Related]
2. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P
Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998
[TBL] [Abstract][Full Text] [Related]
4. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy.
Calvillo-Argüelles O; Abdel-Qadir H; Michalowska M; Billia F; Suntheralingam S; Amir E; Thavendiranathan P
Can J Cardiol; 2019 Feb; 35(2):153-159. PubMed ID: 30760421
[TBL] [Abstract][Full Text] [Related]
6. Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data.
Kim EK; Cho J; Kim JY; Chang SA; Park SJ; Choi JO; Lee SC; Ahn JS; Park SW; Im YH; Jeon ES; Park YH
Cancer Res Treat; 2019 Apr; 51(2):727-736. PubMed ID: 30177584
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction.
Nowsheen S; Aziz K; Park JY; Lerman A; Villarraga HR; Ruddy KJ; Herrmann J
J Am Heart Assoc; 2018 Aug; 7(15):e008637. PubMed ID: 30371238
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
Lynce F; Barac A; Geng X; Dang C; Yu AF; Smith KL; Gallagher C; Pohlmann PR; Nunes R; Herbolsheimer P; Warren R; Srichai MB; Hofmeyer M; Cunningham A; Timothee P; Asch FM; Shajahan-Haq A; Tan MT; Isaacs C; Swain SM
Breast Cancer Res Treat; 2019 Jun; 175(3):595-603. PubMed ID: 30852761
[TBL] [Abstract][Full Text] [Related]
10. Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.
Yu AF; Flynn JR; Moskowitz CS; Scott JM; Oeffinger KC; Dang CT; Liu JE; Jones LW; Steingart RM
JAMA Cardiol; 2020 Mar; 5(3):309-317. PubMed ID: 31939997
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
12. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.
Yu AF; Yadav NU; Lung BY; Eaton AA; Thaler HT; Hudis CA; Dang CT; Steingart RM
Breast Cancer Res Treat; 2015 Jan; 149(2):489-95. PubMed ID: 25552363
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
[TBL] [Abstract][Full Text] [Related]
15. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
[TBL] [Abstract][Full Text] [Related]
16. Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity.
Bergamini C; Dolci G; Rossi A; Torelli F; Ghiselli L; Trevisani L; Vinco G; Truong S; La Russa F; Golia G; Molino A; Benfari G; Ribichini FL
Clin Cardiol; 2018 Mar; 41(3):349-353. PubMed ID: 29569424
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.
Martinello R; Becco P; Vici P; Airoldi M; Del Mastro L; Garrone O; Barone C; Pizzuti L; D'Alonzo A; Bellini E; Milani A; Bonzano A; Montemurro F
Breast J; 2019 May; 25(3):444-449. PubMed ID: 30932296
[TBL] [Abstract][Full Text] [Related]
18. Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.
Kolberg HC; Colleoni M; Demetriou GS; Santi P; Tesch H; Fujiwara Y; Tomasevic Z; Hanes V
Drug Saf; 2020 Mar; 43(3):233-242. PubMed ID: 31927716
[TBL] [Abstract][Full Text] [Related]
19. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
[TBL] [Abstract][Full Text] [Related]
20. Deceleration capacity of heart rate predicts trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer: A prospective observational study.
Feng Y; Qin Z; Yang Z
J Clin Pharm Ther; 2021 Feb; 46(1):93-98. PubMed ID: 32975332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]